Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

This is a phase Ib study to establish safety of Axi-Cel-2 in patients with Large B Cell Lymphoma (LBCL) who are at high risk of relapse.

Trial Details

NCT ID
NCT05794958
Phase
PHASE1
Sponsor
Stanford University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Axicabtagene Ciloleucel
Locations (sample)
  • Palo Alto, California, United States|37.44188,-122.14302

Key Eligibility Criteria

  • Diagnosis: Histologically confirmed aggressive B cell NHL including the following types defined by WHO 2008:
  • Diffuse large B cell lymphoma (DLBCL); OR
  • primary mediastinal (thymic) large B cell lymphoma; OR
  • transformation of follicular lymphoma (TFL), marginal zone lymphoma to DLBCL; OR

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →